Martin Health System broke ground today on its new hospital at the Tradition Center for Innovation (TCI). The 90-bed Tradition Medical Center will provide a valuable resource for research studies taking place at TCI.
Martin Health’s newest facility will be located at the 150-acre research park in the planned community of Tradition in Port St. Lucie, Fla. The anticipated completion date for the 20-acre medical center is set for early 2014 and is expected to create 400 jobs initially and another 400 jobs over the long term.
The vision for the Tradition Medical Center includes a dedicated Phase I Unit for conducting inpatient clinical trials in a variety of disciplines. As TCI looks to bridge the translational gap through collaboration amongst its current research institutions, the Tradition Medical Center will play an integral role in bringing drug and device development from the bench to the clinic.
“Building the Tradition Medical Center at TCI gives us the opportunity to expand our clinical program and provide the local residents with access to a team of dedicated physicians and some of the world’s most promising research,” said Mark Robitaille, president and CEO of Martin Health System.
Having direct access to the hospital’s nationally recognized clinical research program and internal institutional review board allows TCI’s anchor institutes to work with patient samples even in the early stages of clinical development. Martin Health’s approval process outpaces some of the nation’s most well known academic institutions where it can take months to initiate a trial. At Martin Health, programs are approved within two weeks in some cases.
Construction on Mann Research Center’s 60,000 square foot medical office campus that will accompany the new medical center will begin in August 2012. Phase two of construction will produce approximately 80,000 square feet of additional space.
“The addition of Martin Health’s Tradition Medical Center and Mann Research Center’s all-inclusive medical complex makes TCI the ideal setting for fostering collaboration, entrepreneurship, and translational medical advancement,” said Andrew Favata, vice president of Mann Research.